Korean J Hematol 1994; 29(1):
Published online March 31, 1994
© The Korean Society of Hematology
비호지킨 림프종에서 각종 항암화학요법 후 호중구 감소에 대한 재조합인 과립구 집락촉진인자의 투여 효과
서철원, 조구영, 채영란, 도병순, 김도하, 조재근, 김성배, 김상위, 안명주, 이규형, 이정신, 김상희
울산의대 서울중앙병원 내과학교실
Effects of Recombinant Human Granulocyte Colony Stimulating Factor to Prevent Neutropenia After Various Chemotherapy for Non-Hodgkin's Lymphoma
Background: The effects of in vivo recombinant human granulocyte colony stimulating factor(rhG-CSF) on neutropenia have been studying in various malignancies. rhG-CSF is known tobe able to reduce the duration andseverity of
chemotherapy-induced neutropenia. Therefore this study was done to evaluate whether rhG-CSF has any beneficial effect in non-Hodgkin's lymphoma(NHL) management.
Methods: rhG-CSF(Neutrogin) was administered as a daily subcutaneous injection in a dose of 2μg/kg/day for 14 days during the second course of chemotherapy and first
course of chemotherapy without rhG-CSF was evaluated as a control. rhG-CSF therapy was begun 24 hours after the last dose of chemotherapy and was continued until the
absolute neutrophil count(ANC) exceeded 5,000/μL or more.
Results:
1) The nadir of ANC during the first course as a control and the second course with rhG-CSF were 24-684/μL(median : 480/μ1) and 300-4,888/μL(median : 1,995/μL), respectively.
2) The duration of rhG-CSF administration was 2-19 days(median : 8 days).
3) Only one patient complained of mild bone pain which began 3 days after rhG-CSF and relieved after cessation of rhG-CSF administration.
4) According to our grading syst em, 14 cases were very effective, 4 effective and 2 somewhat effective. rhG-CSF was very useful in 13 cases, useful in 5 cases and
somewhat useful in 2 cases.
Conclusion: Our data indicate that rhG-CSF is beneficial for prevention of chemotherapy induced neutropenia in NHL patients.
Keywords Non-Hodgkin's lymphoma; Neutropenia; Recombinant human granulocyte colony stimulating factor; Chemotherapy;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 1994; 29(1): 47-56
Published online March 31, 1994
Copyright © The Korean Society of Hematology.
비호지킨 림프종에서 각종 항암화학요법 후 호중구 감소에 대한 재조합인 과립구 집락촉진인자의 투여 효과
서철원, 조구영, 채영란, 도병순, 김도하, 조재근, 김성배, 김상위, 안명주, 이규형, 이정신, 김상희
울산의대 서울중앙병원 내과학교실
Effects of Recombinant Human Granulocyte Colony Stimulating Factor to Prevent Neutropenia After Various Chemotherapy for Non-Hodgkin's Lymphoma
Cheolwon Suh, Goo Yeong Cho, Young Ran Chae, Byung Soon Doh, Do Ha Kim, Jae, Kun Cho, Sung Bae Kim, Sang We Kim, Myung Ju Ahn, Kyoo Hyung Lee, Jung Shin Lee, Sang, Hee B. Kim
Department of Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea
Abstract
Background: The effects of in vivo recombinant human granulocyte colony stimulating factor(rhG-CSF) on neutropenia have been studying in various malignancies. rhG-CSF is known tobe able to reduce the duration andseverity of
chemotherapy-induced neutropenia. Therefore this study was done to evaluate whether rhG-CSF has any beneficial effect in non-Hodgkin's lymphoma(NHL) management.
Methods: rhG-CSF(Neutrogin) was administered as a daily subcutaneous injection in a dose of 2μg/kg/day for 14 days during the second course of chemotherapy and first
course of chemotherapy without rhG-CSF was evaluated as a control. rhG-CSF therapy was begun 24 hours after the last dose of chemotherapy and was continued until the
absolute neutrophil count(ANC) exceeded 5,000/μL or more.
Results:
1) The nadir of ANC during the first course as a control and the second course with rhG-CSF were 24-684/μL(median : 480/μ1) and 300-4,888/μL(median : 1,995/μL), respectively.
2) The duration of rhG-CSF administration was 2-19 days(median : 8 days).
3) Only one patient complained of mild bone pain which began 3 days after rhG-CSF and relieved after cessation of rhG-CSF administration.
4) According to our grading syst em, 14 cases were very effective, 4 effective and 2 somewhat effective. rhG-CSF was very useful in 13 cases, useful in 5 cases and
somewhat useful in 2 cases.
Conclusion: Our data indicate that rhG-CSF is beneficial for prevention of chemotherapy induced neutropenia in NHL patients.
Keywords: Non-Hodgkin's lymphoma, Neutropenia, Recombinant human granulocyte colony stimulating factor, Chemotherapy,
Previous Article
